Drug Approval | October 09, 2022
Dipharma receives regulatory authorization for the new line at Its cGMP pilot plant
The company increases its efficiency and is able to face the growing demand for its services.
The company increases its efficiency and is able to face the growing demand for its services.
Study achieves primary endpoint of radiographic progression-free survival
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
This win is on the back of a prestigious order from Reliance Life Sciences
Both products are broad-spectrum, foliar insecticides used across wide range of crops
The product will be manufactured at Lupin's facility in Nagpur, India.
The inspection concluded with no observation (FDA-483) issued.
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Subscribe To Our Newsletter & Stay Updated
